WhatsApp Image 2026-07-12 at 10.41.22.jpeg

tomorrow i have my mbbs final year exam of medicine and these are my topics provide me a short notes type all important questions from these topics and their answers

Reading File

Finding Sources

Here are your complete MBBS Final Year Medicine Short Notes - all topics from your list, exam-ready format:

📚 MBBS FINAL YEAR MEDICINE - SHORT NOTES

🩸 HEMATOLOGY

1. IRON DEFICIENCY ANEMIA (IDA)

Definition: Most common anemia worldwide - microcytic, hypochromic anemia due to inadequate iron for Hb synthesis.

Causes (mnemonic HIDE):

H - Hemorrhage (MC cause in adults - GI bleed in men, menorrhagia in women)
I - Inadequate intake (dietary)
D - Decreased absorption (celiac, post-gastrectomy)
E - Excessive demand (pregnancy, growth)

Stages:

Pre-latent - depleted stores, ferritin ↓, no anemia
Latent - serum iron ↓, TIBC ↑, no anemia
Overt IDA - Hb ↓, microcytic hypochromic anemia

Lab findings:

Hb ↓, MCV ↓, MCH ↓, MCHC ↓
Serum ferritin ↓ (most sensitive early test)
Serum iron ↓, TIBC ↑, transferrin saturation ↓ (<15%)
PBS: microcytic hypochromic RBCs, pencil cells, target cells, anisocytosis, poikilocytosis
RDW ↑ (earliest change)

Clinical features:

Pallor, fatigue, exertional dyspnea
Koilonychia (spoon nails), brittle nails
Angular stomatitis, glossitis (beefy red tongue)
Pica (craving for non-food items - clay, ice)
Plummer-Vinson syndrome = IDA + dysphagia + esophageal web

Treatment:

Treat underlying cause
Oral iron: Ferrous sulphate 200 mg TDS (65 mg elemental iron/tab)
Reticulocytosis peaks at 7-10 days
Hb rises 1-2 g/dL per 3 weeks
Continue 3-6 months after Hb normalizes (to replenish stores)
IV iron (Ferric carboxymaltose) if oral not tolerated

2. MEGALOBLASTIC ANEMIA

Definition: Macrocytic anemia with megaloblastic bone marrow changes due to impaired DNA synthesis (B12 or folate deficiency).

Causes:

B12 deficiency: Pernicious anemia (MC), strict vegetarians, gastrectomy, Crohn's disease (terminal ileum), fish tapeworm (Diphyllobothrium latum), blind loop syndrome
Folate deficiency: Poor intake, alcoholism, pregnancy, drugs (methotrexate, phenytoin, trimethoprim), increased demand

Lab findings:

MCV >100 fL (macrocytosis)
PBS: macro-ovalocytes, hypersegmented neutrophils (>5 lobes = pathognomonic), Howell-Jolly bodies
BM: megaloblasts (large cells with open chromatin - "nuclear-cytoplasmic dissociation")
LDH ↑↑, bilirubin ↑ (ineffective erythropoiesis)
B12 <150 pg/mL; Folate <4 ng/mL
Schilling test - to diagnose pernicious anemia

B12 vs Folate deficiency:

Feature	B12	Folate
Neurological	YES (subacute combined degeneration - SACD)	NO
Onset	Slow	Faster
Duration of stores	3-5 years	3-4 months

SACD (Subacute Combined Degeneration):

Posterior column (vibration, proprioception loss) + Lateral column (UMN signs) of spinal cord
Dementia, optic atrophy
Treat with B12 URGENTLY - irreversible if delayed

Treatment:

B12 deficiency: Hydroxocobalamin 1000 mcg IM daily x5, then monthly lifelong
Folate deficiency: Folic acid 5 mg OD x 4 months
NEVER give folate alone in B12 deficiency (precipitates SACD)

3. SICKLE CELL DISEASE (SCD)

Genetics: Autosomal recessive. Point mutation in β-globin gene: Glutamic acid → Valine at position 6.

Pathophysiology: HbS polymerizes under low O2/acidosis/dehydration → sickling → hemolysis + vaso-occlusion

Clinical features:

Vaso-occlusive crisis (most common): Bone pain, hand-foot syndrome (dactylitis) in children
Acute chest syndrome: Fever + chest pain + new infiltrate on CXR (MC cause of death)
Aplastic crisis: Parvovirus B19 infection
Sequestration crisis: Spleen sequesters blood (in young children)
Hemolytic crisis: Increased hemolysis
Stroke, priapism, avascular necrosis of femoral head
Autosplenectomy → susceptible to encapsulated organisms (Pneumococcus, H. influenzae, Meningococcus)
Splenic function lost by age 5

Lab: HbS on electrophoresis, Hb 6-8 g/dL, sickle cells on PBS, elevated reticulocytes

Treatment:

Hydroxyurea (↑ HbF - inhibits sickling)
Folic acid supplementation
Penicillin prophylaxis + vaccinations
Pain crisis: Hydration, analgesics, O2
Exchange transfusion for stroke/acute chest

4. THALASSEMIA

Definition: Hereditary hemolytic anemia due to quantitative defect in globin chain synthesis.

Types:

β-thalassemia: ↓/absent β-chain synthesis
- Thal minor (trait): β/β+ - mild microcytic anemia, usually asymptomatic
- Thal intermedia: moderate
- Thal major (Cooley's anemia): β0/β0 - severe, transfusion-dependent
α-thalassemia: ↓α-chain synthesis (gene deletions)
- 1 gene: Silent carrier
- 2 genes: α-thal trait (mild)
- 3 genes: HbH disease (moderate)
- 4 genes: Hb Bart's (hydrops fetalis - incompatible with life)

β-Thalassemia Major features:

Presents at 6 months (when HbF switches to HbA)
Severe anemia (Hb 2-3 g/dL), splenomegaly, hepatomegaly
Frontal bossing, chipmunk facies, tower skull (crew-cut skull on X-ray)
X-ray: "Hair on end" appearance (skull)
Extramedullary hematopoiesis
Transfusion-dependent

Lab: Hb ↓↓, MCV ↓, MCH ↓, target cells, nucleated RBCs, elevated HbA2 (>3.5%) in β-thal minor

Treatment:

Regular blood transfusions (keep Hb >10)
Chelation therapy: Deferasirox (oral), Desferrioxamine (SC/IV) - to prevent iron overload
Complications of iron overload: Hepatic cirrhosis, cardiac failure, endocrinopathies (DM, hypogonadism)
Curative: Bone marrow transplantation

5. ACUTE MYELOID LEUKEMIA (AML)

Definition: Malignant clonal proliferation of myeloid progenitors (blasts) with >20% blasts in BM.

Classification: FAB M0-M7 (most important: M3 - APML)

Clinical features:

Bone marrow failure: Anemia (pallor, fatigue), thrombocytopenia (bleeding), neutropenia (infections)
Gum hypertrophy, skin infiltration (M4/M5 - monocytic)
Auer rods in blasts (pathognomonic of AML)
DIC especially in M3 (APML - promyelocytic)

Diagnosis:

BM aspirate: >20% myeloblasts
Auer rods on PBS (MPO-positive granules)
Flow cytometry: CD13, CD33, CD117 positive
Cytogenetics: t(15;17) in M3 APML - best prognosis

M3 APML - Special:

t(15;17) - PML/RARα fusion
Severe DIC - life-threatening
Treatment: ATRA (All-trans retinoic acid) + Arsenic trioxide - differentiates blasts → not standard chemo
Best prognosis of all AML

Treatment:

Induction: "7+3" - Cytarabine x7 days + Daunorubicin x3 days
CR achieved in 60-80%
Consolidation: High-dose cytarabine
Allogenic SCT for high-risk

6. CHRONIC MYELOID LEUKEMIA (CML)

Definition: Myeloproliferative neoplasm with clonal expansion of pluripotent stem cell.

Philadelphia chromosome: t(9;22) - BCR-ABL fusion → constitutively active tyrosine kinase → uncontrolled proliferation

Clinical features:

Massive splenomegaly (most prominent finding)
Fatigue, weight loss, night sweats, early satiety
Priapism (rare), gout (hyperuricemia)

Phases:

Chronic phase: <10% blasts - responds to treatment
Accelerated phase: 10-19% blasts, basophilia >20%
Blast crisis: >20% blasts - acute leukemia (myeloid 70%, lymphoid 30%)

Lab:

WBC ↑↑ (often >100,000/μL), whole spectrum of myeloid cells
Low LAP/NAP score (distinguishes from leukemoid reaction)
Basophilia + eosinophilia
Vitamin B12 ↑↑ (from transcobalamin from granulocytes)
Philadelphia chromosome on cytogenetics

Treatment:

Imatinib (Gleevec) - first TKI, revolutionized CML treatment, 400 mg OD
Nilotinib, Dasatinib - 2nd generation TKIs
Goal: Complete cytogenetic remission then molecular remission
Allogenic SCT if TKI failure

7. IMMUNE THROMBOCYTOPENIC PURPURA (ITP)

Definition: Autoimmune destruction of platelets by anti-GPIIb/IIIa antibodies, with normal/↑ megakaryocytes in BM.

Types:

Acute ITP: Children, post-viral (2-6 weeks after URTI), self-limiting (80% resolve spontaneously)
Chronic ITP: Adults (especially women 20-40), >12 months duration

Clinical features:

Purpura (non-palpable, petechiae), bruising
Mucosal bleeding (epistaxis, gingival)
Intracranial hemorrhage (rare but serious, platelet <20,000)
Spleen - normal size (important distinction)

Lab:

Platelet ↓↓ (often <30,000), others normal
BM: ↑ megakaryocytes (normal/increased)
Anti-platelet IgG antibodies (not routinely tested)

Treatment:

Platelet >50,000: Observe
Platelet 20,000-50,000 + symptoms: Prednisolone 1 mg/kg/day
Platelet <20,000 or bleeding: IVIG 1 g/kg x2 days (rapid, for emergencies)
Splenectomy: For chronic, steroid-refractory ITP (removes site of both antibody production and platelet destruction)
Romiplostim, Eltrombopag: TPO receptor agonists for refractory

8. VON WILLEBRAND DISEASE (VWD)

Definition: Most common inherited bleeding disorder. Deficiency/dysfunction of vWF (vWF bridges platelet to collagen and carries Factor VIII).

Types:

Type 1 (most common, 70%): Quantitative partial deficiency - Autosomal dominant
Type 2: Qualitative defect
Type 3: Severe quantitative deficiency - Autosomal recessive

Clinical features:

Mucocutaneous bleeding (epistaxis, menorrhagia, gingival)
Prolonged bleeding after cuts/dental extractions
NOT deep muscle/joint bleeds (unlike hemophilia)

Lab:

Bleeding time ↑↑ (platelet plug formation impaired)
aPTT ↑ (if vWF very low → Factor VIII falls)
PT normal
vWF antigen ↓, Ristocetin cofactor activity ↓
Platelet count NORMAL

Treatment:

DDAVP (Desmopressin): For Type 1 - releases vWF from endothelial stores
vWF concentrate/Factor VIII concentrate: Type 3 and surgery
Avoid aspirin, NSAIDs

9. HEMOPHILIA A

Definition: X-linked recessive deficiency of Factor VIII. Affects males; females are carriers.

Severity:

Severe: Factor VIII <1% (spontaneous bleeds)
Moderate: 1-5%
Mild: 5-40% (bleeds only with trauma/surgery)

Clinical features:

Hemarthrosis (joint bleeds) - most common, MC joint: KNEE
Muscle hematomas (iliopsoas)
Deep tissue bleeds
Intracranial hemorrhage
NO petechiae, NO mucosal bleeding (platelet function normal)

Lab:

aPTT ↑↑ (intrinsic pathway defect)
PT normal, TT normal, platelets normal, BT normal
Factor VIII assay: ↓

Treatment:

Factor VIII concentrate (recombinant preferred)
DDAVP: For mild hemophilia A (releases Factor VIII from endothelium)
Avoid aspirin/NSAIDs
Hemophilia B = Factor IX deficiency (Christmas disease) - same presentation, different treatment (Factor IX)

🦴 RHEUMATOLOGY

10. RHEUMATOID ARTHRITIS (RA)

Definition: Chronic systemic autoimmune inflammatory arthritis primarily affecting synovial joints.

Pathology: CD4+ T cells, TNF-α, IL-1, IL-6 → synovitis → pannus → joint destruction

Clinical features:

Joint involvement: Symmetrical, small joints of hands (PIP, MCP - spares DIP), wrists, feet
Early morning stiffness >1 hour (hallmark)
Warm, tender, swollen joints
Deformities: Ulnar deviation, Boutonniere deformity, Swan-neck deformity, Z-thumb
Extra-articular: Rheumatoid nodules (extensor surface, 20%), interstitial lung disease, pleural effusion, vasculitis, scleritis, Felty syndrome (RA + splenomegaly + neutropenia), pericarditis

ACR/EULAR 2010 Criteria (score ≥6/10):

Joint involvement (0-5)
Serology: RF or anti-CCP (0-3)
Acute phase reactants: CRP/ESR (0-1)
Duration >6 weeks (1)

Lab:

RF (Rheumatoid factor): +ve in 70-80% (not specific)
Anti-CCP (anti-cyclic citrullinated peptide): Most specific (95%), present early
ESR ↑, CRP ↑, normocytic normochromic anemia
X-ray: Soft tissue swelling → periarticular osteopenia → joint space narrowing → erosions

Treatment:

NSAIDs: Symptom relief
DMARDs: Methotrexate (MTX) - anchor drug, started early
Other DMARDs: Hydroxychloroquine, Sulfasalazine, Leflunomide
Biologics: TNF inhibitors (Infliximab, Etanercept, Adalimumab), IL-6 inhibitor (Tocilizumab), CD20 (Rituximab)
Short-term steroids for flares

11. SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

Definition: Systemic autoimmune disease with multiorgan involvement due to immune complex deposition.

Mnemonic: MD SOAP HAIR (ACR criteria, ≥4 needed):

M - Malar rash (butterfly rash - spares nasolabial folds)
D - Discoid rash
S - Serositis (pleuritis, pericarditis)
O - Oral ulcers (painless)
A - Arthritis (non-erosive)
P - Photosensitivity
H - Hematologic (hemolytic anemia, leukopenia, thrombocytopenia)
A - ANA positive
I - Immunologic (anti-dsDNA, anti-Sm, antiphospholipid Ab)
R - Renal (proteinuria >0.5 g/day, cellular casts)
- Neurological (seizures, psychosis)

Important antibodies:

ANA: >95% sensitive (screening test, not specific)
Anti-dsDNA: Most specific, correlates with disease activity and nephritis
Anti-Sm: Most specific (not disease activity)
Anti-Ro/La: Neonatal lupus, secondary Sjögren
Antiphospholipid Ab (anti-cardiolipin, lupus anticoagulant): Thrombosis, recurrent miscarriage

Lupus nephritis: Most serious complication, WHO class III/IV worst prognosis. Hematuria, proteinuria, hypertension, renal failure.

Treatment:

Mild: Hydroxychloroquine (all SLE patients), NSAIDs
Moderate/Severe: Prednisolone
Severe/Nephritis: Cyclophosphamide + steroids or Mycophenolate mofetil
Biologics: Belimumab (anti-BLyS)

12. GOUT

Definition: Monosodium urate crystal deposition in joints/tissues due to hyperuricemia (uric acid >7 mg/dL in males).

Pathogenesis: Hyperuricemia → MSU crystals → activate inflammasome → IL-1β → acute inflammation

Causes of hyperuricemia:

Underexcretion (90%): Renal causes, thiazides, cyclosporine
Overproduction (10%): High purine diet, myeloproliferative disorders, tumor lysis syndrome, HPRT deficiency (Lesch-Nyhan)

Stages:

Asymptomatic hyperuricemia
Acute gout attack
Intercritical gout
Chronic tophaceous gout

Clinical:

Acute attack: Exquisite pain, redness, swelling, warmth of joint
1st MTP joint = Podagra (MC first joint involved, classic presentation)
Triggers: Alcohol, red meat, seafood, trauma, surgery, illness
Tophi: Chronic urate deposits (ear helix, Achilles tendon, olecranon)
Renal: Uric acid stones, gouty nephropathy

Diagnosis: Joint aspiration - negatively birefringent needle-shaped crystals (yellow when parallel to compensator axis)

Lab: Uric acid ↑, WBC ↑ in joint fluid (>50,000 PMNs), elevated ESR/CRP during attack

Treatment:

Acute attack: NSAIDs (indomethacin), Colchicine, steroids
Prophylaxis/chronic: Allopurinol (xanthine oxidase inhibitor - reduces uric acid production), Febuxostat
Probenecid: Uricosuric agent (↑ renal excretion)
Do NOT start allopurinol during acute attack (worsens)

🏥 HEPATOLOGY

13. VIRAL HEPATITIS

Feature	HepA	HepB	HepC	HepD	HepE
Virus	RNA	DNA	RNA	RNA (needs HBV)	RNA
Transmission	Fecal-oral	Blood/sexual/perinatal	Blood	Blood	Fecal-oral
Incubation	2-6 wk	6-24 wk	2-26 wk	Co/superinfect	2-8 wk
Chronicity	No	10%	80%	Yes	No
Cirrhosis	No	Yes	Yes	Yes	No
HCC	No	Yes	Yes	Yes	No
Vaccine	Yes	Yes	No	HepB prevents	Yes

HBV Serology (must know):

HBsAg: Surface antigen = current infection (appears first)
HBeAg: High infectivity, active replication
HBcAb IgM: Acute infection / window period
HBsAb: Past infection / vaccination (immunity)
HBcAb IgG: Past infection (not vaccination)
Window period: HBsAg gone, HBsAb not yet appeared - only HBcAb IgM positive

Acute HBV Management: Supportive. Antivirals generally not needed for acute. Chronic HBV Treatment: Tenofovir, Entecavir (nucleotide/nucleoside analogues); Pegylated IFN-α HCV Treatment: Sofosbuvir + Ledipasvir (DAAs) - 95%+ cure rate, 12 weeks

14. CIRRHOSIS

Definition: End-stage liver disease with diffuse fibrosis and nodule formation replacing normal architecture.

Causes: Alcohol (MC in West), HBV/HCV (MC in Asia/India), NASH, autoimmune, Wilson's, hemochromatosis

Complications:

Portal hypertension
Ascites
Variceal bleeding
Hepatic encephalopathy
Hepatorenal syndrome
Spontaneous bacterial peritonitis (SBP)
Hepatocellular carcinoma (HCC)

Child-Pugh Score (prognosis):

Bilirubin, Albumin, PT/INR, Ascites, Encephalopathy
Class A (5-6), B (7-9), C (10-15) - C = worst prognosis

Features of Portal Hypertension:

Ascites, splenomegaly, esophageal varices, caput medusae, hemorrhoids
Normal portal pressure <5 mmHg; Clinically significant >10 mmHg

Ascites management: Salt restriction, spironolactone (first-line), furosemide; Large volume paracentesis + albumin for tense ascites; TIPS for refractory

SBP: Ascitic fluid PMN >250 cells/μL; Treat: Cefotaxime 2 g IV; Prophylaxis: Norfloxacin 400 mg OD

Hepatic Encephalopathy:

Precipitants: GI bleed, infection, constipation, sedatives, electrolyte imbalance
Treatment: Lactulose (titrate to 2-3 soft stools/day), Rifaximin
Asterixis (flapping tremor) = key sign

15. PORTAL HYPERTENSION

Definition: Portal pressure >10 mmHg (normal 5-10 mmHg) or HVPG (hepatic venous pressure gradient) >5 mmHg.

Classification:

Pre-hepatic: Portal vein thrombosis, splenic vein thrombosis
Intra-hepatic: Cirrhosis (MC), schistosomiasis
Post-hepatic: Budd-Chiari syndrome, right heart failure, constrictive pericarditis

Features: Splenomegaly, varices (esophageal, gastric, anorectal), ascites, caput medusae

Variceal Bleeding Management:

Resuscitate, Terlipressin (splanchnic vasoconstrictor) or Octreotide
Endoscopic variceal ligation (EVL) or sclerotherapy
Antibiotics (norfloxacin/ceftriaxone) - reduce mortality
Sengstaken-Blakemore tube: For uncontrolled bleeding
TIPSS: For refractory bleeding

Primary prophylaxis: Non-selective beta-blocker (Propranolol/Carvedilol)

16. AMOEBIC LIVER ABSCESS (ALA)

Etiology: Entamoeba histolytica (right lobe MC)

Pathology: Amoeba invades colonic mucosa → portal vein → liver → abscess (classic "anchovy sauce" pus = reddish-brown)

Clinical features:

Fever (high grade, remittent)
Right hypochondrial pain (MC symptom)
Tender hepatomegaly
Dysentery may NOT be present (only 30-40% have concurrent dysentery)
Rupture: Right pleura/lung, pericardium (dangerous)

Investigations:

USG: Best initial investigation - hypoechoic lesion in right lobe
Serology (ELISA): Amoebic antibodies (>95% sensitive)
FNAC: Anchovy sauce pus, no organisms usually seen
LFT: ALP ↑↑ (disproportionate)
Stool examination for cysts

Treatment:

Metronidazole 750 mg TDS x10 days (drug of choice)
Followed by Luminal amoebicide: Diloxanide furoate 500 mg TDS x10 days (to eradicate intestinal cysts)
Aspiration: If >5 cm, no response in 72h, or pericardial extension risk

🦠 INFECTIOUS DISEASES

17. ENTERIC FEVER (TYPHOID)

Causative agent: Salmonella typhi (typhoid), S. paratyphi A/B/C (paratyphoid)

Transmission: Fecal-oral (contaminated food/water)

Pathogenesis: Ingestion → Peyer's patches in terminal ileum → MLN → bloodstream (bacteremia) → fever

Clinical features (week by week):

Week 1: Fever (stepladder pattern rising to 39-40°C), headache, malaise, constipation
Week 2: Continuous high fever, relative bradycardia (Faget sign), splenomegaly, rose spots (2-4 mm, on abdomen, fade on pressure, in 30%)
Week 3: Complications - intestinal perforation (MC), GI bleeding, hepatitis, myocarditis
Week 4: Defervescence and recovery

Diagnosis:

Week 1-2: Blood culture (gold standard, positive 90%)
Widal test: O antigen ≥1:160, H antigen ≥1:160 (significant in non-endemic area; O>H = active infection)
Stool/urine culture: Week 3 onwards
Typhidot (IgM/IgG dot assay): Quick, useful

Treatment:

Ceftriaxone 2g IV OD x14 days (drug of choice for severe)
Fluoroquinolones (Ciprofloxacin): Increasing resistance
Azithromycin: For uncomplicated, oral
Steroids: For severe toxemia/encephalopathy (Dexamethasone)
Perforation: Surgery

Carrier state: >3 months after recovery. Treat with Ciprofloxacin x4 weeks.

18. DENGUE

Virus: Dengue virus (DENV 1-4), Flavivirus. Vector: Aedes aegypti mosquito.

Clinical classification:

Dengue without warning signs
Dengue with warning signs
Severe dengue (DSS/DHF)

Warning signs: Abdominal pain, persistent vomiting, mucosal bleeding, rapid breathing, lethargy, liver enlargement >2 cm, rising hematocrit with rapid platelet fall

Classic dengue:

Sudden high fever (2-7 days), "breakbone fever" (severe myalgia/arthralgia)
Flushed face, rash (maculopapular/petechial)
Retro-orbital pain
Tourniquet test positive (capillary fragility test)

DHF/DSS (Dengue Hemorrhagic Fever/Shock Syndrome):

Thrombocytopenia (<100,000), capillary leak syndrome
Pleural effusion, ascites, bleeding
Dengue shock syndrome = narrow pulse pressure (<20 mmHg) or hypotension

Lab:

NS1 antigen: Positive in first 5 days (early diagnosis)
IgM: Positive from day 5-7 (MAC-ELISA)
CBC: Leukopenia, rising hematocrit, thrombocytopenia
LFT: AST/ALT mildly elevated (AST>ALT)

Treatment:

No specific antiviral
Dengue without warning signs: Oral fluids, paracetamol (NOT aspirin/NSAIDs/ibuprofen)
Dengue with warning signs/severe: IV crystalloids, strict fluid monitoring
Platelet transfusion: Only if <10,000 or active bleeding

19. MALARIA

Parasite: Plasmodium falciparum (most dangerous), P. vivax, P. ovale, P. malariae, P. knowlesi. Vector: Female Anopheles mosquito.

Life cycle: Liver phase (exo-erythrocytic) → Blood phase (erythrocytic, causes symptoms) → Gametocyte (infects mosquito)

Feature	P. falciparum	P. vivax
Fever pattern	Irregular/quotidian	Tertian (every 48h)
RBCs affected	All sizes	Young/enlarged
Relapse	No	Yes (hypnozoites in liver)
Cerebral malaria	Yes	Rare
Severity	Severe	Mild-moderate

Severe malaria (all P. falciparum):

Cerebral malaria (coma, seizures)
Severe anemia (Hb <7)
Blackwater fever (massive hemolysis → hemoglobinuria → dark urine)
ARDS, hypoglycemia, renal failure, thrombocytopenia

Diagnosis:

Peripheral blood smear (PBS): Gold standard - ring forms (falciparum = applique/accole, multiple rings), banana-shaped gametocytes (falciparum)
RDT (Rapid diagnostic test): HRP-2 (falciparum), pLDH
QBC (Quantitative Buffy Coat)
PCR: Most sensitive

Treatment:

Uncomplicated falciparum: Artemisinin-based combination therapy (ACT) - Artesunate-Mefloquine/Lumefantrine
Severe malaria: IV Artesunate (preferred) or IV Quinine
P. vivax/ovale: Chloroquine + Primaquine (kills hypnozoites to prevent relapse)
Primaquine: Check G6PD before giving (causes hemolysis in G6PD deficiency)

20. TUBERCULOSIS (TB)

Organism: Mycobacterium tuberculosis (acid-fast bacillus)

Primary TB: Initial infection - Ghon focus (subpleural focus in lower/mid lung) + hilar lymph nodes = Ghon complex. Usually asymptomatic, self-limiting.

Secondary/Post-primary TB: Reactivation - upper lobe (better O2), cavitation, fibrosis.

Clinical features:

Constitutional: Fever (evening rise), night sweats, weight loss, fatigue
Pulmonary: Cough >2 weeks, hemoptysis, breathlessness
Chest X-ray: Upper lobe infiltrates, cavities, calcifications, hilar lymphadenopathy

Extrapulmonary TB:

TB meningitis (lymphocytic pleocytosis, high protein, low glucose)
Miliary TB (hematogenous spread - millet seed shadows)
TB lymphadenitis (MC extrapulmonary)
Pott's disease (vertebral TB - D10-L2 MC)
TB pericarditis, TB peritonitis

Diagnosis:

Sputum AFB smear (Ziehl-Neelsen stain) - 3 samples
GeneXpert/Xpert MTB/RIF: Detects TB + rifampicin resistance (WHO recommended)
Sputum culture: Gold standard but takes 6-8 weeks (LJ medium)
Mantoux test: >10 mm significant (>5 mm in immunocompromised)
IGRA (Interferon-gamma release assay): Better specificity than Mantoux

Treatment - RIPE:

Intensive phase (2 months): HRZE (Isoniazid + Rifampicin + Pyrazinamide + Ethambutol)
Continuation phase (4 months): HR (Isoniazid + Rifampicin)

Drug side effects:

Isoniazid (H): Peripheral neuropathy (prevent with Pyridoxine/B6), hepatitis
Rifampicin (R): Orange urine, hepatitis, enzyme inducer
Pyrazinamide (Z): Hyperuricemia, hepatitis
Ethambutol (E): Optic neuritis (retrobulbar, color vision loss first)
Streptomycin: Ototoxicity, nephrotoxicity

MDR-TB: Resistant to at least H+R. Treat with second-line drugs.

🧠 NEUROLOGY

21. HEADACHE

Primary headaches (no structural cause):

A. Migraine:

Unilateral, pulsating, moderate-severe pain, 4-72h
Associated: Nausea/vomiting, photophobia, phonophobia
Aura (in 30%): Visual (zigzag/fortification spectrum), sensory, motor
Triggers: Stress, menstruation, foods (cheese, chocolate, wine), sleep changes
Treatment:
- Acute: Triptans (5-HT1B/1D agonists) - Sumatriptan; NSAIDs, antiemetics
- Prophylaxis: Propranolol, Topiramate, Amitriptyline, Valproate

B. Tension-type headache (most common headache):

Bilateral, pressing/squeezing, mild-moderate, 30 min-7 days
No nausea/vomiting, no photophobia+phonophobia together
Treatment: NSAIDs, Paracetamol, Amitriptyline (prophylaxis)

C. Cluster headache:

Severe unilateral periorbital pain, 15-180 min
Autonomic features: Lacrimation, nasal congestion, ptosis, miosis, conjunctival injection
Occurs in clusters (same time of day/year), more common in men, smoking
Treatment:
- Acute: High-flow O2 (100%, 12-15 L/min), Sumatriptan SC/nasal
- Prophylaxis: Verapamil (drug of choice)

Secondary headaches:

"Red flag" features (SNOOP): Sudden onset (thunderclap), Neurological deficit, Onset >50, Orthostatic, Papilledema, Progressive
Thunderclap headache: SAH until proven otherwise (LP after CT head)

22. STROKE

Definition: Focal neurological deficit due to cerebrovascular disease lasting >24 hours.

Classification:

Ischemic (85%): Thrombotic, embolic, lacunar
Hemorrhagic (15%): Intracerebral hemorrhage (ICH), subarachnoid hemorrhage (SAH)

TIA: Same symptoms resolving completely in <24 hours (usually <1 hour); MRI may show infarct.

Ischemic stroke - FAST:

Face drooping, Arm weakness, Speech difficulty, Time to call emergency

Risk factors: Hypertension (most important/modifiable), DM, dyslipidemia, AF, smoking, carotid stenosis

Management of Ischemic Stroke:

CT head immediately (to exclude hemorrhage before thrombolysis)
IV tPA (Alteplase) within 4.5 hours of onset (contraindicated in hemorrhage, BP >185/110, recent surgery)
Mechanical thrombectomy (large vessel occlusion) within 24 hours
Aspirin 300 mg within 24-48 hours (NOT if thrombolysis given in first 24h)
BP: Allow permissive hypertension (lower only if >220/120)

Hemorrhagic stroke:

ICH: Hypertension MC cause, immediate BP control (systolic <140), reverse anticoagulation, surgical evaluation
SAH: Thunderclap headache, CT head (blood in cisterns), LP if CT negative (xanthochromia), Berry aneurysm (most common cause), Nimodipine (prevent vasospasm)

ABCD2 score for TIA (stroke risk prediction):

Age >60, BP >140/90, Clinical features (unilateral weakness=2, speech=1), Duration, Diabetes
Score >4 = high risk, needs urgent evaluation

🫀 CARDIOLOGY

23. ANGINA PECTORIS

Definition: Chest pain/discomfort due to myocardial ischemia (demand > supply) without infarction.

Types:

Stable angina: Predictable, on exertion, relieved by rest/GTN within 5 min
Unstable angina (ACS): New onset, at rest, increasing frequency/severity, not relieved by 3 GTN doses
Prinzmetal/Variant angina: Coronary vasospasm, at rest, young women, ST elevation during episode, responds to nitrates and CCBs

Investigations:

ECG at rest: May be normal
TMT (Treadmill test/exercise ECG): >1 mm ST depression = positive
Coronary angiography: Gold standard

Treatment of Stable Angina:

Risk factor modification
GTN sublingual: Acute relief
Beta-blockers: First-line chronic (reduce heart rate and O2 demand)
CCBs (amlodipine): Alternative
Long-acting nitrates: Isosorbide mononitrate
Aspirin + Statin: All patients
Revascularization (PCI/CABG) for refractory angina

24. MYOCARDIAL INFARCTION (MI)

Definition: Myocardial cell necrosis due to prolonged ischemia (usually >20 min) - acute rupture of atherosclerotic plaque.

STEMI vs NSTEMI:

Feature	STEMI	NSTEMI
ECG	ST elevation + new LBBB	ST depression / T-wave changes
Troponin	↑↑	↑
Mechanism	Total occlusion	Partial occlusion
Treatment	Immediate reperfusion	Medical ± PCI

ECG changes in STEMI (time course):

Minutes: Hyperacute T waves
Hours: ST elevation, new Q waves
Days: T-wave inversion
Weeks: Q waves persist (permanent)

Cardiac biomarkers:

Troponin I/T: Most sensitive and specific; rises 3-6h, peaks 12-24h, normalizes 7-14 days
CK-MB: Rises 4-6h, peaks 12-24h, normalizes 2-3 days (useful for reinfarction)
LDH: Rises 24-48h, lasts 14 days (oldest marker - now rarely used)
Myoglobin: Earliest to rise (1-3h), not specific

Complications of MI:

Immediate: Arrhythmias (VF = MC cause of death in first 24h), cardiac arrest
Early (1-3 days): Pericarditis (Dressler's at 2-10 weeks)
1 week: Papillary muscle rupture (acute MR, flash pulmonary edema), VSD, free wall rupture (hemopericardium, tamponade)
Late: LV aneurysm (persistent ST elevation), Dressler's syndrome

Treatment (STEMI):

MONABASH: Morphine, O2, Nitrates, Aspirin + Ticagrelor/Clopidogrel, Beta-blocker, ACE inhibitor, Statin, Heparin
Primary PCI: Within 90 min - gold standard
Thrombolysis (Streptokinase/tPA): If PCI not available within 120 min

25. ACUTE RHEUMATIC FEVER (ARF)

Etiology: Group A beta-hemolytic Streptococcus (GAS/S. pyogenes) pharyngitis (not skin infection)

Pathogenesis: Molecular mimicry - anti-streptococcal antibodies cross-react with cardiac antigens

Jones Criteria (2015 revised): Major: JONES

J - Joint (migratory polyarthritis - MC manifestation)
O - \O/ Pancarditis (carditis - MC cause of long-term damage)
N - Nodules (subcutaneous, painless)
E - Erythema marginatum (rash with clear center)
S - Sydenham's chorea (involuntary movements, emotional lability)

Minor: Fever, elevated ESR/CRP, prolonged PR interval, previous ARF

Diagnosis: 2 major OR 1 major + 2 minor + evidence of recent Strep infection (ASO titre ↑, throat culture, rapid Ag test)

Treatment:

Eradicate Streptococcus: Benzathine penicillin IM single dose (or oral Penicillin V x10 days)
Anti-inflammatory: Aspirin (for arthritis), Steroids (for carditis)
Chorea: Haloperidol, valproate

Prophylaxis (MOST IMPORTANT):

Benzathine penicillin 1.2 MU IM every 3 weeks (every 4 weeks also used)
Duration: Without carditis = 5 years or till age 21; With carditis = 10 years or till age 40; With persistent rheumatic heart disease = lifelong

26. HYPERTENSION

Definition (JNC 8 / 2018 ACC/AHA):

Normal: <120/80
Elevated: 120-129/<80
Stage 1: 130-139/80-89
Stage 2: ≥140/≥90
Hypertensive crisis: >180/120
- Emergency: With target organ damage
- Urgency: Without target organ damage

Target Organ Damage (BEAN):

B - Brain: Stroke, TIA, encephalopathy
E - Eyes: Hypertensive retinopathy (Keith-Wagener-Barker grades I-IV)
A - Arteries: Aortic dissection, PVD
N - Heart+kNey: LVH, HF, renal failure

Secondary HTN causes: Renal artery stenosis (bruit, young women = FMD), primary hyperaldosteronism (Conn's), pheochromocytoma, Cushing's, coarctation of aorta, OCP

Treatment:

Lifestyle: DASH diet, weight loss, Na restriction (<2g/day), exercise, stop smoking/alcohol
First-line drugs: ACE inhibitor/ARB, CCB, Thiazide diuretic
JNC 8 guidelines: For general population ≥60 yrs: target <150/90; <60 yrs: <140/90
Compelling indications:
- DM/CKD: ACE inhibitor or ARB
- Heart failure/post-MI: ACE inhibitor + beta-blocker
- Black patients: CCB or thiazide (ACE inhibitors less effective)
- Pregnancy: Methyldopa, Labetalol (avoid ACE/ARB - teratogenic)

27. AORTIC STENOSIS (AS)

Etiology: Calcific degeneration (elderly MC), bicuspid aortic valve (young), Rheumatic

Hemodynamics: LV outflow obstruction → LV pressure overload → LV hypertrophy → heart failure

Classic triad (SAD):

S - Syncope (exertional) - worst prognosis
A - Angina (exertional)
D - Dyspnea (LVF)

Survival after symptoms: Angina = 5 years, Syncope = 3 years, Heart failure = 2 years (SAD → 5-3-2)

Signs:

Slow-rising, plateau pulse (pulsus parvus et tardus)
Ejection systolic murmur (crescendo-decrescendo) at aortic area, radiates to carotids
Soft/absent A2, S4 gallop
Narrow pulse pressure
Left ventricular heave

Diagnosis: Echo = gold standard (valve area <1 cm² = severe, gradient >40 mmHg = severe)

Treatment:

No medical therapy prevents progression
Surgical aortic valve replacement (SAVR): Gold standard for eligible patients
TAVI/TAVR: For high surgical risk patients (transcatheter aortic valve implantation)

28. MITRAL STENOSIS (MS)

Etiology: Almost always Rheumatic fever (RHD). Commissural fusion, leaflet thickening.

Pathophysiology: LA outflow obstruction → LA pressure ↑ → pulmonary congestion → pulmonary HTN → RVF

Mitral valve area: Normal = 4-6 cm²; Significant <2 cm²; Severe <1 cm²

Clinical features:

Dyspnea on exertion (most common), orthopnea, PND
Hemoptysis (pulmonary hypertension)
AF (most common arrhythmia - LA dilatation)
Systemic embolism (from LA thrombus in AF)
Malar flush (MS facies - pinkish-purple cheeks)

Signs:

Tapping apex beat (palpable S1)
Opening snap (OS) + mid-diastolic rumbling murmur (low-pitched, at apex, louder in left lateral position with bell)
Short S2-OS interval = more severe
Loud S1 (pliable valve), loud P2 (pulmonary HTN)

Investigations:

CXR: Straight left heart border, double right heart border, splaying of carina (LA enlargement), Kerley B lines, pulmonary edema
ECG: P-mitrale (bifid P in lead II), AF
Echo: Valve area, gradient, commissure fusion

Treatment:

Rate control: Beta-blockers, digoxin (for AF)
Anticoagulation: Warfarin for AF or prior embolism
PMV/PTMC (Percutaneous transvenous mitral commissurotomy): Definitive for pliable valve without calcification or MR
Surgical: MVR (mitral valve replacement) for calcified/unsuitable valves

29. CONGENITAL HEART DISEASE (CHD)

Acyanotic CHDs (left to right shunt, no cyanosis initially):

ASD (Atrial Septal Defect):

Fixed, wide split S2 (diagnostic)
Pulmonary ejection systolic murmur
MC type: Ostium secundum (70%)
CXR: Cardiomegaly, pulmonary plethora
Eisenmenger: When L→R reverses to R→L (irreversible)

VSD (Ventricular Septal Defect - Most common CHD):

Harsh pansystolic murmur at lower left sternal border
Spontaneous closure in 50% in childhood
Roger's disease: Small hemodynamically insignificant VSD

PDA (Patent Ductus Arteriosus):

Continuous "machinery" murmur (under left clavicle)
Bounding pulses, wide pulse pressure
Closure: Indomethacin (if premature infant), Surgical ligation

Cyanotic CHDs (right to left shunt):

TOF (Tetralogy of Fallot - MC cyanotic CHD):

4 components: VSD, Overriding aorta, Pulmonary stenosis, RVH
Boot-shaped heart on CXR
Tet spells (hypercyanotic episodes): Baby squats to ↑ SVR
Treatment: Propranolol (for spells), surgical repair

Transposition of Great Arteries (TGA):

Aorta from RV, Pulmonary artery from LV
Egg-on-side CXR appearance
Survival needs mixing: ASD, VSD, PDA
Emergency: Prostaglandin E1 to keep PDA open

🫁 RESPIRATORY MEDICINE

30. ASTHMA

Definition: Chronic inflammatory airway disease with reversible airflow obstruction, airway hyperresponsiveness, and airway remodeling.

Pathophysiology: Allergens → IgE-mediated mast cell degranulation → histamine, leukotrienes → bronchoconstriction + mucosal edema + mucus hypersecretion

Triggers: Allergens, cold air, exercise, smoke, NSAIDs (aspirin-exacerbated), viral infections

Clinical features:

Episodic wheezing, breathlessness, chest tightness
Symptoms worse at night/early morning
Diurnal variation in PEFR (>20% variation diagnostic)

Investigations:

Spirometry: Obstructive pattern - FEV1/FVC <70%, post-bronchodilator FEV1 ↑>12% and 200 mL = reversibility
PEFR: Variability >20% over 2 weeks
Bronchial provocation (methacholine): For diagnosis when spirometry normal

Severity:

Intermittent → Mild Persistent → Moderate Persistent → Severe Persistent
GINA classification based on symptoms, SABA use, lung function

Treatment (stepwise GINA):

SABA (Salbutamol): Reliever - all patients as needed
Step 2: Low-dose ICS (inhaled corticosteroid) - e.g., Budesonide
Step 3: ICS + LABA (Salmeterol/Formoterol)
Step 4: Medium/high ICS + LABA
Step 5: Add oral corticosteroids, biologics (Omalizumab for allergic asthma, Dupilumab)

Acute severe asthma (status asthmaticus):

SpO2 <92%, PEFR <50%, unable to talk in sentences
Treatment: O2, Salbutamol nebs (continuous), Ipratropium nebs, IV Hydrocortisone/oral Prednisolone, Magnesium sulphate IV (smooth muscle relaxation), ICU if not improving

31. CHRONIC BRONCHITIS (Part of COPD)

Definition: Productive cough for ≥3 months/year for ≥2 consecutive years without other cause.

Blue Bloater vs Pink Puffer:

Feature	Chronic Bronchitis (Blue Bloater)	Emphysema (Pink Puffer)
Build	Obese/overweight	Thin, cachectic
Cough	Productive, early	Minimal
Dyspnea	Later	Early, prominent
Cyanosis	Yes (blue)	No (pink)
Cor pulmonale	Common	Less common
Hypoxia	Significant	Mild

COPD Management (GOLD):

Stop smoking (single most important intervention)
SABA/SAMA: As needed reliever
LABA + LAMA: Foundation of stable COPD maintenance
ICS only if ≥2 exacerbations/year or eosinophils >300
Pulmonary rehabilitation
Oxygen therapy: If PaO2 <55 mmHg at rest (long-term O2 prolongs life)
NIPPV for acute exacerbations with respiratory failure

32. PLEURAL EFFUSION

Definition: Abnormal accumulation of fluid in pleural space.

Transudate vs Exudate (Light's Criteria): Exudate if ANY of:

Pleural/serum protein ratio >0.5
Pleural/serum LDH ratio >0.6
Pleural LDH >2/3 upper limit of normal serum LDH

Type	Causes	Fluid
Transudate	CCF, cirrhosis, nephrotic syndrome, hypoalbuminemia	Clear, low protein
Exudate	Pneumonia, TB, malignancy, PE	Turbid, high protein

Special effusions:

Chylothorax: Milky fluid, triglycerides >110
Hemothorax: Pleural/serum Hb >0.5
Empyema: Pus, frank infection, needs drainage + antibiotics

Investigations:

CXR: Blunting of costophrenic angle (250 mL+), homogeneous opacity, mediastinum shifts AWAY from effusion (except in atelectasis/mesothelioma)
USG chest: Best for guidance of thoracocentesis
Diagnostic tap + analysis (pH, glucose, protein, LDH, cytology, culture)

Treatment: Treat underlying cause, thoracocentesis (diagnostic and therapeutic), intercostal drain (ICD) for large/empyema

33. PNEUMOTHORAX

Definition: Air in pleural space.

Types:

Spontaneous primary: No underlying disease, tall thin young men (ruptured bleb)
Spontaneous secondary: COPD, asthma, TB, Marfan, CF
Traumatic
Iatrogenic (post-procedure)

Tension pneumothorax (medical emergency):

Air enters pleura but cannot escape
Trachea deviated AWAY from affected side
Absent breath sounds + hyperresonance on affected side
Hypotension, tachycardia, JVP ↑
Immediate needle decompression (2nd ICS, midclavicular line) - DON'T wait for CXR!

Small (<2 cm) primary pneumothorax: Observe, O2 (100% O2 speeds absorption) Large (>2 cm): Aspiration or ICD insertion

34. PNEUMONIA

Community-Acquired Pneumonia (CAP):

Common pathogens by age:

Young adults: S. pneumoniae (MC), Mycoplasma, Chlamydophila
Elderly: S. pneumoniae, Gram-negative (Klebsiella), anaerobes (aspiration)
Immunocompromised: PCP (Pneumocystis jirovecii), fungal, atypical

Typical vs Atypical:

Feature	Typical (S. pneumoniae)	Atypical (Mycoplasma, Chlamydia, Legionella)
Onset	Abrupt	Gradual
Productive cough	Yes (rusty sputum)	Dry cough
Consolidation	Yes	No (diffuse infiltrates)
CXR	Lobar	Patchy bilateral
Gram stain	Organisms visible	Negative

Severity scoring: CURB-65 (1 point each):

Confusion (new)
Urea >7 mmol/L
Respiratory rate ≥30
BP systolic <90 or diastolic ≤60
Age ≥65
Score 0-1: Home; 2: Hospital; 3-5: ICU

Treatment:

Mild (CURB-65 0-1): Oral Amoxicillin ± Clarithromycin
Moderate (2): IV Amoxicillin + Clarithromycin
Severe (3-5): IV Co-amoxiclav + Clarithromycin/Azithromycin; Anti-MRSA if risk
Atypical (Legionella): Fluoroquinolone or Macrolide

35. COAL WORKER'S PNEUMOCONIOSIS (CWP) / PNEUMOCONIOSIS

Occupational lung disease from inhaled inorganic dust.

Types:

Disease	Dust	Pathology	X-ray
CWP	Coal dust	Coal macule, Caplan's syndrome	Upper zone nodules
Silicosis	Silica (quartz)	Silicotic nodule (birefringent)	Eggshell calcification of hilar nodes
Asbestosis	Asbestos	Ferruginous bodies, pleural plaques	Bilateral lower zone fibrosis, pleural plaques
Berylliosis	Beryllium	Granulomas (like sarcoidosis)	Bilateral infiltrates

Coal Worker's Pneumoconiosis:

Simple CWP: Small nodules (<10 mm), upper zones
Progressive Massive Fibrosis (PMF): Nodules >10 mm, massive upper lobe fibrosis
Caplan's syndrome: CWP + RA = large necrotic nodules

Asbestosis - Most clinically important:

Diseases caused: Asbestosis (lung fibrosis), Pleural plaques (MC manifestation), Mesothelioma (pleural malignancy), Lung cancer (synergistic with smoking)
Golden yellow/brown asbestos bodies ("dumbbell-shaped") in sputum
Mesothelioma: Bloody pleural effusion, not related to smoking, very poor prognosis
Asbestos → Mesothelioma (latency 20-40 years)

Silicosis:

Sandblasters, stone cutters, tunnel workers
Eggshell calcification of hilar lymph nodes (pathognomonic)
Silicosis increases risk of TB (silicotuberculosis)

📝 QUICK EXAM MNEMONICS SUMMARY

Topic	Mnemonic
ARF Jones criteria	JONES + minor (2 major or 1 major + 2 minor)
SLE criteria	MD SOAP HAIR
AML Auer rods	MPO positive, pathognomonic
CML	Philadelphia chromosome t(9;22), low LAP
IDA	Ferritin first to fall
MS signs	OS, MDM, tapping apex
AS triad	SAD (Syncope-Angina-Dyspnea) = 3-5-2 years
CURB-65	Pneumonia severity
Dengue early test	NS1 <5 days, IgM >day 5
Malaria severe	Always P. falciparum
TB drugs	HRZE x2 + HR x4
Ethambutol SE	Eyes (optic neuritis)
Isoniazid SE	Neuropathy (give B6)

All the best for your exam tomorrow! 🎯 You have covered every topic on the board. Focus on the classic exam questions: criteria, investigations, and first-line treatments for each condition.

This is a shared conversation. Sign in to Orris to start your own chat.